Hyperglycemia
Conditions
Brief summary
The aim of the project is to examine whether the sources of n-3 fatty acids and fish itself differ in their effects on glucose metabolism, lipid metabolism, blood pressure, and serum inflammatory markers. Lipidomic profiles and gene expression will be used for thorough assessment of the possible clinical changes. The study will compare the effects of alpha-linolenic acid containing vegetable oil, fatty fish, lean fish and control diet. The results of this project will help to identify the optimal source of n-3 fatty acids, and reveal the significance of the components of fish other than fatty acids. These data will be useful both nationally and internationally, since highly controlled dietary interventions utilizing new methodology are scarce.
Interventions
Sponsors
Kuopio University Hospital
VTT Technical Research Centre, Finland
University of Eastern Finland
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* age 40-70 years * BMI 25-32 kg/m2 * fasting plasma glucose 5.6-7.0 mmol/l * 2 h plasma glucose in oral glucose tolerance test \<=11 mmol/l * fasting serum total cholesterol \<=7 mmol/l * fasting serum LDL cholesterol \<=5 mmol/l * fasting serum triglycerides \<=4 mmol/l
Exclusion criteria
* any chronic disease or condition that hamper the ability to follow dietary intervention * chronic liver, thyroid or kidney disease * alcohol abuse * diabetes * recent weight loss * recent myocardial infarction * corticosteroid therapy * psychiatric disorders which need drug treatment * cancer under treatment * fish allergy or other extensive food allergies * exceptional diets (like Atkin's or vegan diet)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gene expression in adipose tissue and peripheral blood mononuclear cells | Baseline and 12 weeks | Change in gene expression in adipose tissue and peripheral blood mononuclear cells |
| Glucose metabolism assessed by oral glucose tolerance test and frequently sampled intravenous glucose tolerance test | Baseline and 12 weeks | change in glucose metabolism |
| Serum lipid profile | Baseline and at 12 weeks | Change in serum lipid profile |
| Blood pressure | Baseline and 12 weeks | Change in blood pressure |
| Serum inflammatory markers | baseline and 12 weeks | Change in serum inflammatory markers |
| Plasma and adipose tissue lipidomic profile | Baseline and 12 weeks | Change in plasma and adipose tissue lipidomic profile |
| Plasma and urine metabonomics | Baseline and 12 weeks | Change in plasma and urine metabonomics |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reverse cholesterol transport | Baseline and 12 weeks | Change in reverse cholesterol transport |
Countries
Finland
Outcome results
None listed